Myostatin Inhibitors Can Build Bigger Muscles — But Not Stronger Ones
Myostatin inhibitor trials add muscle mass on MRI without gains in grip strength or walk tests. Peter Attia's four hypotheses for why size and function split.
FDA Puts Aging on Its Regulatory Science Agenda — What That Actually Means
The FDA added aging to its regulatory science agenda. It signals seriousness about longevity but creates no new trial pathway or approval. What it does mean.
The Longevity Biotech 100x Return Is Real — But It's Social Value, Not Investor Profit
A model puts $366.8 trillion of social value on therapies adding 10 years of life, against $3.3 trillion in costs. Why that 100x isn't an investor return.
Insilico Medicine's 287% Revenue Jump: AI Drug Discovery Is Becoming Real Pharma Revenue
Insilico Medicine grew to $106M revenue in H1 2026 on $7.3B in total deal value with Eli Lilly, Servier, and others — and a 90% gross margin that confirms AI drug pipelines have crossed from research promise to commercial scale.
Mount Sinai's $1M XPRIZE Bet: Can the Immune System Be Reset to Fight Aging?
Mount Sinai secured $1M in XPRIZE Healthspan funding to run NYC-Vita, a trial combining lifestyle and medication to restore immune function decades lost to aging.
Whole-Body MRI Is Leaving the Biohacker Bubble
EHE Health's partnership with Prenuvo brings whole-body MRI screening into 200+ preventive care clinics. What this transition from biohacker niche to medical infrastructure means for longevity-minded members.
The Antiaging Trial That Just Won $1M From XPRIZE to Test in Humans
AgelessRx has been selected as one of 10 Milestone 2 awardees in the $101M XPRIZE Healthspan competition, earning $1M to advance a one-year randomized trial testing a six-component antiaging protocol including low-dose rapamycin, NAD+, and metformin.
5 Perimenopause Supplements That Actually Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are under-dosed marketing. This evidence-graded breakdown identifies five options that hold up on clinical data, labeled doses, and standardized extracts.
Aging Research Has Been Studying the Wrong Sex
The Reproductive Resilience Hypothesis, published in Cell, argues female biology holds the key to understanding longevity — but most aging research has treated it as experimental noise.
One Shot, Five Organs: FGF21 Gene Therapy Extends Mouse Healthspan by 20%
A single AAV injection of FGF21 extended median lifespan by over 20% in aged mice, protecting liver, kidneys, heart, muscle, and brain — and it worked after age-related decline had already begun.
Scientists Reversed 'Permanent' Aging Damage in Human Tissue. Here's What Was Fixed.
A Nature Communications study showed an engineered enzyme (CMLase) removed advanced glycation end products from human arterial, skin, and lens tissue — reversing damage long considered irreversible.
The $10 Billion Probiotic Problem: What the Evidence Shows and What Works Instead
The probiotic market generates $10 billion per year despite evidence that most commercial supplements don't persist in the gut. Here's what the studies say—and five mechanistically stronger alternatives.
GARM's Klotho Longevity Residency Brought 22 Participants to Honduras. Here's What They're Testing.
A four-day longevity residency at the Kimpton Grand Roatán included a proprietary Klotho intervention, blood sampling before and after, and researchers from MIT and Harvard. GARM is betting that Klotho is the next longevity biomarker to watch.
Rapalogix: $20M to Bring Rapamycin Anti-Aging Science to Skincare
Rapalogix Health raised a $20M Series A to expand rapamycin-based skincare targeting TORC1 — the cellular pathway behind systemic longevity interventions, now applied topically.
Geroscience Is Rewriting the Logic of Disease Prevention
Thirty percent of centenarians escape major age-related disease entirely — not by treating conditions as they arrive, but by aging differently. Geroscience targets the shared biological mechanisms underlying multiple diseases simultaneously. Here's where the clinical evidence stands in 2026.
The World's First Human Kidney Regeneration Surgery Is Scheduled for July 2026
Rokit Healthcare has clinical approval to begin the first human kidney regeneration trial using AI-assisted 3D bioprinting and robotic surgery with the patient's own omentum-derived cells — a milestone that sidesteps transplant waiting lists entirely.
China Launches the World's First 2,000-Person Stem Cell Antiaging Trial
Beijing's 301 Hospital is running the largest stem cell trial ever attempted for aging prevention, shifting longevity science from disease treatment toward systemic intervention.
Immorta Bio's Combination Therapy Reports 70%+ Lifespan Extension in Animal Models
A peer-reviewed study combining senolytic immunotherapy with stem cell regeneration shows dramatic lifespan gains. What the animal data does and doesn't tell us.
VERVE-102 and the Beginning of the End of Atherosclerosis
A Phase I trial published in the New England Journal of Medicine shows VERVE-102, a one-time base-editing gene therapy, can cut PCSK9 protein levels by up to 88% and LDL cholesterol by up to 62% — potentially permanently — in high-risk cardiovascular patients.
Plasma Exchange Cuts Blood Microplastics by 60%: First Clinical Data
A May 2026 study in the Journal of Clinical Apheresis found therapeutic plasma exchange reduced blood microplastic levels from 52.2 to 21.1 particles per 100µL — the first peer-reviewed data on clinically removing microplastics from circulation.
Battery-Free Brain Implant Leaves the Lab: ABILITY Neurotech's ALS Trial
ABILITY Neurotech's optical-link BCI received approval for chronic home use in ALS patients — the first time this class of device moves from controlled demonstrations to real-world daily use.
Growth Hormone for Injury Recovery: The Evidence Gap Between Clinics and Clinical Trials
hGH reliably raises IGF-1. IGF-1 drives anabolic signaling. Somewhere between that mechanism and the recovery outcomes being sold in wellness clinics, the evidence breaks down.
Scribe Therapeutics' STX-1150: Silencing PCSK9 Epigenetically Without Editing Your DNA
Scribe's STX-1150 cuts LDL 50%+ in primates for 18 months from a single dose — silencing PCSK9 epigenetically, not by altering the DNA sequence itself.
Ossium Health: The Case for Rebuilding the Immune System From Scratch
PRESERVE I trial: all 4 patients achieved full donor chimerism and remained relapse-free at Day 180 using banked deceased-donor bone marrow. What this means for longevity.
Fasting as Regenerative Medicine: What the FMD Data Actually Shows
Dr. Valter Longo's clinical trials show fasting-mimicking cycles reduce biological age by 2.5 years and helped 60-70% of diabetes patients reduce medications. The mechanism isn't weight loss.
Ultra-Processed Foods Cut Sperm Motility 18% in Just Three Weeks
3 weeks of ultra-processed food cut sperm motility 18% and testosterone 11% in a controlled trial — without eating extra calories. The mechanism matters.
MBX 4291 Monthly GLP-1 Shows 7% Weight Loss at Eight Weeks
MBX 4291 hit 7% weight loss at 8 weeks with a 26-day half-life supporting true once-monthly dosing — and Phase 1 data shows no serious safety signals.
EL-22: The Engineered Probiotic Targeting the Muscle Loss That GLP-1 Drugs Leave Behind
NorthStrive Biosciences has patented EL-22, a myostatin-inhibiting probiotic designed to preserve lean muscle during GLP-1-driven weight loss — addressing one of the category's most significant side effects.
Rapamycin + Exercise: Why the First Real Trial Disappointed
Rapamycin may blunt exercise gains in older adults. Peter Attia: this trial is underpowered—but the HbA1c signal is real.
Lipid-Lowering Pharmacotherapy: The Decision That Actually Determines Outcomes
92 million Americans take statins, but which lipid-lowering drug you take matters less than matching it to your dominant cholesterol pathway. Here's the framework.
Inbrain's Graphene Brain Interface: First Human Trial Results Signal a New Class of Neural Device
Inbrain's graphene cortical interface completed its first 8-patient human trial with no device-related adverse events — a safety milestone for a neural recording technology designed to be thinner and more biocompatible than conventional silicon.
Your Workout May Train Your Kids Too: Peter Attia's April 2026 Research Roundup
Paternal exercise reprograms sperm microRNAs that improve offspring endurance capacity. Plus: autonomic nervous system imbalance as a unifying theory of aging. Four studies from Attia's April roundup.
Cataracts and Dementia Risk: The Surprisingly Simple Brain-Protection Lever
A meta-analysis of 558,276 participants finds cataract surgery associated with 25% lower dementia risk. Vision correction may be one of the most accessible cognitive interventions in aging.
NLRP3: The Inflammasome Switch Linking Aging to Chronic Disease
NLRP3 links obesity, Alzheimer's, and aging through a single inflammasome. Suppressing it extended mouse lifespan 34%. Q2 2026 clinical trial data is due.
VITAL-H: The $38M Trial Testing Rapamycin, Ozempic, and Farxiga Against Aging
A federally funded trial at UT Health San Antonio is testing three FDA-approved drugs in 726 healthy adults aged 60–65 to see if aging itself can be slowed with existing medications.
Obicetrapib: The Drug Targeting Both Heart Disease and Alzheimer's at Once
A CETP inhibitor in late-stage trials cut LDL by up to 50% while reducing Alzheimer's biomarkers. The BROADWAY trial data may represent a new category of longevity drug.
One Man's Alzheimer's Mutation Isn't Causing Dementia. Heat Shock Proteins May Be Why.
A 75-year-old with a dominant Alzheimer's mutation remains cognitively healthy. Heat shock proteins may explain why — and what it means for brain longevity research.
Mimio: The Fasting Mimetic With a Peer-Reviewed RCT Behind It
Mimio's randomized placebo-controlled trial in Nature Scientific Reports shows reduced LDL, fasting glucose, and oxidized LDL in 8 weeks — without dietary changes or actual fasting.
GRAIL's Trial Missed Its Endpoint. That's Not the Same as Failing.
Peter Attia's analysis of GRAIL's landmark cancer screening trial: a missed composite endpoint doesn't tell you whether multi-cancer early detection technology works.
The Industrialization of Longevity: Clinical Rigor and the End of Biohacking Hype
Analyzing the transition from experimental biohacking to clinical validation, driven by ARPA-H funding and new FDA regulatory frameworks.
The Klotho Protocol: Architecting the Future of Cognitive Resilience
Klothea initiates the first longevity-focused human trial of mRNA-based klotho therapy, marking a shift from theoretical anti-aging to clinical bio-architecture.
Longevity Trials and Environmental Risks: Navigating the Future of Biohacking
Exploring the breakthrough Klotho therapy trials and the emerging threat of nanoplastics in the brain.